AFT-19 prostate cancer trial comparing apalutamide combinations posts results, marked completed
Alliance Foundation Trials' Phase 3 study testing apalutamide-based regimens against LHRH monotherapy in biochemically relapsed prostate cancer posted results after completion, with Janssen as collaborator.
One item updated this week for this trial record.
- "A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer" (NCT03009981, sponsor ID AFT-19) is a Phase 3 trial sponsored by Alliance Foundation Trials, LLC, with Janssen Research & Development, LLC as collaborator. The study, which enrolled men with biochemically recurrent prostate cancer and PSA doubling time of 9 months or less, had results first posted on 2026-11-09, the same date as its last update, after reaching study completion on 2025-06-25.1 The trial randomized 503 participants1 across three arms, testing LHRH analogue monotherapy against combinations adding apalutamide, and apalutamide plus abiraterone acetate and prednisone. The primary endpoint was PSA progression-free survival in the intent-to-treat population.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.